This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated
by Zacks Equity Research
Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance.
Compared to Estimates, Exelixis (EXEL) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXEL vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug
by Zacks Equity Research
Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.
GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia
by Zacks Equity Research
GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.
Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week
by Zacks Equity Research
Rocket Pharmaceucticals (RCKT) soars 53.8% in a week on news of alignment with the FDA for the mid-stage study of RP-A501, an investigational gene therapy for treating Danon Disease.
Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico
by Zacks Equity Research
Exelixis (EXEL) enters into a license agreement with Insilico Medicine for ISM3091, a potentially best-in-class USP1 inhibitor.
J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe
by Zacks Equity Research
J&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the accelerated pathway.
Bristol Myers' (BMY) Pulmonary Fibrosis Drug Positive in Phase II
by Zacks Equity Research
Bristol Myers (BMY) posts encouraging data from a phase II study in progressive pulmonary fibrosis.
Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study
by Zacks Equity Research
Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.
CymaBay (CBAY) Stock Up on Positive Results From PBC Study
by Zacks Equity Research
CymaBay (CBAY) reports encouraging data from the phase III study of seladelpar in PBC patients. Stock up.
Illumina (ILMN) Down 14.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit
by Zacks Equity Research
The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.
Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.
AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication
by Zacks Equity Research
AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.
Roche's (RHHBY) Application for PNH Drug Accepted by FDA
by Zacks Equity Research
Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.
EXEL vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids
by Zacks Equity Research
Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.
Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.
Exelixis (EXEL) Stock Gains 41.8% So Far in 2023: Here's Why
by Zacks Equity Research
Exelixis' (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Its efforts to develop additional drugs to expand its portfolio are poised to reap rewards for the company.
Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.